Leuprolide plus donepezil may stabilize memory loss in Alzheimer's disease
the ONA take:
According to a new study published in the Journal of Alzheimer's Disease, researchers have found that leuprolide, a drug commonly used for androgen deprivation therapy for patients with prostate cancer, stabilized memory loss for a year in women with Alzheimer's disease.
For the study, researchers enrolled 109 women with mild to moderate Alzheimer's disease. Some women were treated with high-dose leuprolide acetate and donepezil, an acetylcholinesterase inhibitor that treats symptoms of Alzheimer's disease.
Other patients received an acetylcholinesterase inhibitor plus low-dose leuprolide or placebo. Results showed that those treated with donepezil and high-dose leuprolide had nearly no decline in their ADAS-cog score, a memory test, while those treated with an acetylcholinesterase inhibitor plus low-dose leuprolide or placebo experienced declines after 1 year.
Previous studies have suggested the leuprolide has protective benefits for Alzheimer's disease. One study found that men treated with leuprolide for prostate cancer were 34-55% less likely to develop Alzheimer's disease compared with men who did not receive the injection.
The researchers suggest that this promising drug combination should be tested in patients with early and late stages of the disease, but because the company that initially conducted this research is now out of business, it is unclear whether this therapy will be further developed.
Leuprolide stabilized memory loss for a year in women with Alzheimer's disease.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|